Standard of care updates in ovarian cancer: PARP inhibitors
Mansoor Raza Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, speaks on the landmark trials from ESMO 2019 regarding PARP…
Related Articles
Phase III trial of rinatabart sesutecan in platinum-resistant ovarian cancer
Angeles Secord, MD, Duke Cancer Institute, Durham, NC, gives an overview of the Phase III RAINFOL-02 trial (NCT06619236) evaluating rinatabart sesutecan (Rina-S) versus investigator’s choice…
Clinical implementation of ctDNA monitoring for NSCLC
Aslaug Helland, MD, PhD, University of Oslo, Oslo, Norway, emphasizes the need for standardization in studies on circulating tumor cells (CTCs) and cell-free DNA (cfDNA)…
Tissue-selective estrogen complexes as a new treatment for DCIS
Swati Kulkarni, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, comments on the significance of the PROMISE study (NCT02694809) of conjugated estrogen/bazedoxifene (CE/BZA) for…
The future landscape of treatment intensification strategies for TNBC
Christian Singer, Medical University of Vienna, Vienna, Austria, highlights the challenges of post-neoadjuvant achievement treatments in patients triple-negative breast cancer (TNBC) who haven’t achieved complete…
TALENTACE: TACE combined with atezolizumab + bevacizumab in uHCC
Lorenza Rimassa, MD, Hunimed University, Milan, Italy, discusses TALENTACE (NCT047126430), a positive Phase III Asian trial combining atezolizumab-bevacizumab with on-demand TACE versus TACE alone in…
Real-world impact of bevacizumab with pembrolizumab in cervical cancer
Alberto Farolfi, MD, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)
The future of HER2-directed therapies in non-small cell lung cancer
Joshua Sabari, MD, New York University Langone Health, New York, NY, provides an overview of the growing options in the HER2 space for non-small cell…
Utilizing midkines to improve outcomes in SCLC and MCC
Curtis Perry, MD, PhD, Yale University, New Haven, CT, describes the benefits of identifying midkines in immune resistant Merkel cell carcinoma (MCC) and small cell…
Improving early clinical trial enrolment in pediatric oncology
Lesleigh Abbott, MD, The Children’s Hospital of Eastern Ontario, Ottawa, Canada, gives an overview of barriers to early-phase clinical trial enrolment for pediatric patients with…
Reforming the treatment landscape in melanoma with T-cell therapies
Martin Wermke, MD, TU Dresden University of Technology, Dresden, Germany, shares his insight into the emerging T-cell therapies for patients with melanoma and their impact…